Related Experiment Video
Updated: Jun 7, 2025
04:16
Intraoperative Visualization of Subretinal Injection and Retinal Detachment in Rats
Published on: March 7, 2025
273
Cabozantinib-Associated Exudative Retinal Detachment and Choroiditis: A Case Report
Kirk A J Stephenson1, Bryon R McKay1, Katherine E Paton1
1Department of Ophthalmology and Visual Sciences, University of British Columbia, Vancouver, BC, Canada.
Journal of Current Ophthalmology
|November 18, 2024
Summary
This case report details the first instance of acute chorioretinal inflammation caused by cabozantinib in a metastatic renal cell carcinoma patient. Early intervention with medication cessation and treatment resolved the vision issues.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Background:
- Cabozantinib is a tyrosine kinase inhibitor used for metastatic cancers.
- Ocular adverse events are common with modern cancer therapies.
- Early detection and management of side effects are crucial.
Observation:
- A 54-year-old male developed blurred vision after starting cabozantinib for metastatic renal cell carcinoma.
- Ophthalmic findings included bilateral exudative retinal detachments and choroiditis, mimicking Vogt-Koyanagi-Harada disease.
- Latent tuberculosis was also identified.
Findings:
- Cabozantinib cessation, corticosteroids, anti-TB therapy, and methotrexate led to recovery.
- Visual function and ocular anatomy normalized within one month.
Implications:
- Cabozantinib can induce a severe chorioretinal inflammatory response.
- This highlights the importance of ophthalmologic monitoring in patients receiving cabozantinib.
- Multifaceted treatment approaches are effective for managing these ocular toxicities.
